Ginkgo Biloba Extract
Evidence Fact Sheet
standardized · EGb 761
Ginkgo biloba standardized extract (EGb 761; 24% flavone glycosides / 6% terpene lactones) is a botanical studied for cognition, circulation, tinnitus and blood pressure. PAF antagonism + antioxidant mechanisms; research dose 120-240 mg/day. Permitted as a supplement (DSHEA); EU has 0 authorized health claims. Evidence is mixed with notable negatives.
Also known as: Ginkgo Biloba · GBE · EGb 761 · Ginkgolide B (PAF antagonist constituent)
Overview
Ginkgo biloba extract is a standardized botanical (most clinical work uses EGb 761, normalized to 24% flavone glycosides and 6% terpene lactones, with ginkgolic acids kept below 5 ppm). Proposed mechanisms include platelet-activating-factor (PAF) antagonism by ginkgolide B, free-radical scavenging by flavone glycosides, and modulation of microcirculation and neurotransmitter pathways. Clinical research typically uses 120-240 mg/day in 2-3 divided doses; the US supplement market median is roughly 80 mg. Regulatory status is permissive but unendorsed: a dietary supplement under DSHEA in the US, marketed under EMA herbal monographs in the EU (EFSA has authorized 0 health claims), and a registered health-food raw material in China. PAF antagonism carries a theoretical bleeding-risk signal with anticoagulant/antiplatelet drugs. This page reports research findings in studied populations and is not disease-treatment guidance.
Mechanism of Action
Platelet-activating factor (PAF) antagonism (ginkgolide B) · ROS/RNS scavenging by flavone glycosides · NO pathway / microcirculation modulation · NF-κB pathway inhibition · Neurotransmitter (ACh/dopamine/5-HT) modulation
Body systems: Neurological & Cognitive · Cardiovascular · Vision · Blood & Hematopoiesis · Auditory & Vestibular · Autonomic Nervous System
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Ginkgo Biloba Extract is not characterized as a treatment for any disease.
Cognition in Mild Dementia (Symptomatic Treatment)
Meta-analysis supported- p = 0.04cognition vs placebo
- p = 0.01activities of daily living
A meta-analysis pooling four RCTs of standardized EGb 761 at 240 mg/day in patients already diagnosed with mild dementia found it significantly superior to placebo across cognition, global assessment, daily-living function and quality of life, with standardized effects described as medium to large and no excess adverse events. This is the symptomatic-treatment context (existing mild dementia), which contrasts with the negative prevention trials in healthy elderly.
Reported effect: 240 mg EGb 761 daily superior to placebo: cognition p = 0.04, global assessment p = 0.01, activities of daily living p = 0.01, quality of life p = 0.02; standardized effects medium to large; adverse-event frequency p = 0.66
“Treatment with 240 mg EGb 761 daily was significantly superior to placebo in cognition (p = 0.04), global assessment (p = 0.01), activities of daily living (p = 0.01) and quality of life (p = 0.02).”
Source: PMID 39895346 · Riepe 2025 · World J Biol Psychiatry
Dementia Prevention in Healthy/Normal-Cognition Elderly
Null / no benefit RCT supported- HR 1.12all-cause dementia · 95% CI 0.94-1.33
- P = .21not significant
The large GEM Study (Ginkgo Evaluation of Memory), a JAMA-published RCT, randomized 3,069 community elderly with normal cognition or mild cognitive impairment to 120 mg twice daily versus placebo. Ginkgo did not reduce the incidence of all-cause dementia or Alzheimer disease. This is the headline honest negative for using ginkgo to PREVENT dementia in healthy people, distinct from symptomatic treatment of established mild dementia.
Reported effect: All-cause dementia HR 1.12 (95% CI 0.94-1.33; P = .21); Alzheimer disease HR 1.16 (95% CI 0.97-1.39; P = .11)
“In this study, G. biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI.”
Source: PMID 19017911 · DeKosky 2008 · JAMA
Dementia / Cognitive Impairment (Overall Evidence Synthesis)
Null / no benefit Meta-analysis supported- 36 trialsCochrane review
- 2,016 patients9 six-month trials
- 3 of 4recent trials null
This Cochrane systematic review of 36 trials concluded that the evidence for a predictable, clinically significant cognitive benefit is inconsistent and unreliable, with three of the four most recent trials finding no difference from placebo. Ginkgo was, however, judged as safe as placebo. This is the broad-evidence counterweight to individual positive EGb 761 trials.
Reported effect: 36 trials included; in 9 six-month trials (2,016 patients) results were inconsistent; 3 of 4 most recent trials found no difference vs placebo
“The evidence that Ginkgo biloba has predictable and clinically significant benefit for people with dementia or cognitive impairment is inconsistent and unreliable.”
Source: PMID 19160216 · Birks 2009 · Cochrane Database Syst Rev
Peripheral Circulation / Intermittent Claudication (Walking Distance)
Null / no benefit Meta-analysis supported- 14 trials739 participants
- 3.57ACD kcal · 95% CI -0.10 to 7.23
- P = 0.06not significant
A Cochrane review of 14 trials in peripheral arterial disease found only a small, non-significant increase in absolute claudication (pain-free walking) distance, with the confidence interval crossing zero. The authors concluded there is no evidence of a clinically significant benefit for patients with peripheral arterial disease.
Reported effect: Absolute claudication distance increase 3.57 kcal (95% CI -0.10 to 7.23; P = 0.06), ~64.5 m on a flat treadmill; 14 trials, 739 participants
“The ACD increased with an overall effect size of 3.57 kilocalories (CI -0.10 to 7.23, P = 0.06) compared with placebo. This translates to an increase of just 64.5 (CI -1.8 to 130.7) metres on a flat treadmill ... Overall, there is no evidence that Ginkgo biloba has a clinically significant benefit for patients with peripheral arterial disease.”
Source: PMID 23744597 · Nicolaï 2013 · Cochrane Database Syst Rev
Tinnitus (Primary Complaint)
Null / no benefit Meta-analysis supported- 4 trials1,543 participants
- 3 trials1,143 with primary tinnitus
A Cochrane review of four trials (1,543 participants) found that in the three trials where tinnitus was the primary complaint (1,143 participants), ginkgo showed no evidence of effectiveness. Small reductions appeared only in a subgroup whose tinnitus was secondary to dementia, not in people with tinnitus as their main problem.
Reported effect: 4 trials, 1,543 participants; in 3 trials (1,143 participants) with primary tinnitus, no evidence of effectiveness; dementia subgroup (400 participants) showed ~1.5 points (vascular dementia) and 0.7 points (Alzheimer) on a 10-point scale
“A small but statistically significant reduction of 1.5 and 0.7 points was seen in patients taking Gingko biloba with vascular dementia and Alzheimer's disease respectively ... The limited evidence does not demonstrate that Ginkgo biloba is effective for tinnitus when this is the primary complaint.”
Source: PMID 23543524 · Hilton 2013 · Cochrane Database Syst Rev
Blood Pressure in Essential Hypertension
Null / no benefit Meta-analysis supported- 9 RCTs1,012 patients
- 6 vs 3trials positive vs not significant
A systematic review of 9 RCTs (1,012 hypertensive patients) found mixed results: six trials suggested a potential blood-pressure-lowering effect of ginkgo as complementary therapy, but three found no statistically significant effect on systolic or diastolic blood pressure. The authors drew no confirmative conclusion and called for more rigorous trials.
Reported effect: 9 RCTs, 1,012 hypertensive patients; 6 trials showed potential positive BP effect, 3 trials no statistically significant effect on SBP/DBP; no confirmative conclusion
“6 trials demonstrated potential positive effect of GBE as complementary therapy on BP reduction when compared with antihypertensive drug therapy; however, it was not associated with a statistically significant effect on both SBP and DBP reduction in 3 other trials.”
Source: PMID 24877716 · Xiong 2014 · Phytomedicine
Dosage (research context · not a recommendation)
Standardized extract (24% flavone glycosides / 6% terpene lactones · ginkgolic acids <5 ppm) · clinical research 120-240 mg/day in 2-3 divided doses; US market median ~80 mg (educational reference, not a recommendation)
Regulatory Status · 4 Markets
- US · FDA
- Dietary supplement under DSHEA · no affirmative FDA GRAS determination for standalone Ginkgo biloba (the single GRN mentioning ginkgo — GRN 36 — covered a chromium-picolinate / ginkgo / ginseng combination, and FDA ceased its evaluation at the notifier's request) · structure/function claims permissible (no disease claims) · DSLD ~431 products, median 80 mg
- EU · EFSA
- EMA Ginkgo folium herbal monograph splits two regimes: well-established use for age-related mild cognitive impairment / quality of life in mild dementia, and traditional use for minor circulatory complaints (heaviness in legs, cold hands/feet) — national marketing authorisations rely on this monograph · EFSA: 0 authorized health claims (2012 cognitive/circulation claim applications rejected)
- CN · China
- Listed on SAMR health-food raw-material catalogue; registered blue-hat function 'assists memory improvement'; standardized spec (flavone glycosides >=24%, terpene lactones >=6%, ginkgolic acid <5 ppm).
- BR · ANVISA
- Listed in Memento Fitoterápico (ANVISA herbal medicine list) · dietary supplement and THR pathways both available
Safety
PAF antagonism produces a bleeding-risk signal: theoretical/clinical interaction with warfarin, aspirin, NSAIDs, and anticoagulant/antiplatelet drugs — discontinue ~2 weeks before surgery. Caution in seizure disorders (ginkgotoxin may lower seizure threshold). Use only standardized extract with ginkgolic acids <5 ppm (un-standardized crude leaf may contain allergenic/genotoxic ginkgolic acids). SSRI/MAOI co-use caution. Consult a healthcare provider; not a substitute for prescription anticoagulant or cerebrovascular therapy.
Related
Goals: cognitive-support
Lifestyles: senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 39895346 · Riepe 2025 · World J Biol Psychiatry — Cognition in Mild Dementia (Symptomatic Treatment)
- PMID 19017911 · DeKosky 2008 · JAMA — Dementia Prevention in Healthy/Normal-Cognition Elderly
- PMID 19160216 · Birks 2009 · Cochrane Database Syst Rev — Dementia / Cognitive Impairment (Overall Evidence Synthesis)
- PMID 23744597 · Nicolaï 2013 · Cochrane Database Syst Rev — Peripheral Circulation / Intermittent Claudication (Walking Distance)
- PMID 23543524 · Hilton 2013 · Cochrane Database Syst Rev — Tinnitus (Primary Complaint)
- PMID 24877716 · Xiong 2014 · Phytomedicine — Blood Pressure in Essential Hypertension
Frequently Asked Questions
1. Does ginkgo biloba prevent dementia in healthy older adults?
The evidence says no. The large JAMA-published GEM RCT (PMID 19017911) randomized 3,069 elderly with normal cognition or mild cognitive impairment to 120 mg twice daily versus placebo and found ginkgo did not reduce all-cause dementia (HR 1.12, 95% CI 0.94-1.33) or Alzheimer disease. This is a research finding about prevention in healthy people and is not treatment advice.
2. Is there any cognitive context where ginkgo showed a benefit?
Yes, but in a different population. A meta-analysis of four RCTs (PMID 39895346) found standardized EGb 761 at 240 mg/day was superior to placebo on cognition (p = 0.04) and daily-living function (p = 0.01) in people who already had mild dementia. This symptomatic-treatment signal contrasts with the negative prevention results, and a broad Cochrane review of 36 trials (PMID 19160216) still calls the overall dementia evidence inconsistent and unreliable.
3. Does ginkgo help tinnitus or improve walking distance in poor circulation?
Cochrane reviews found no clinically significant benefit for either when they are the primary problem. For tinnitus as a primary complaint, the review of four trials (PMID 23543524) found no evidence of effectiveness; for peripheral arterial disease, the review of 14 trials (PMID 23744597) found only a small, non-significant change in claudication distance (3.57 kcal, 95% CI -0.10 to 7.23).
4. What form and dose is used in ginkgo research, and is it regulated?
Clinical trials almost always use standardized EGb 761 (24% flavone glycosides, 6% terpene lactones, ginkgolic acids below 5 ppm) at 120-240 mg/day in divided doses; the US market median is around 80 mg. It is permitted as a dietary supplement under DSHEA in the US and marketed under EMA herbal monographs in the EU, though EFSA has authorized 0 health claims. Because of its PAF-antagonist bleeding-risk signal, caution is warranted with anticoagulant or antiplatelet drugs. This is regulatory and research-dose context, not a personal recommendation.
Last evidence review: 2026-06-13